Brilacidin, a host defense peptide mimetic, potentiates ibrexafungerp antifungal activity against the human pathogenic fungus Aspergillus fumigatus [PDF]
Microbiology SpectrumAspergillus fumigatus is the primary etiological agent of aspergillosis. Here, we show that the host defense peptide mimetic brilacidin (BRI) can potentiate ibrexafungerp (IBX) against clinical isolates of A. fumigatus.
Thaila Fernanda dos Reis +4 more
doaj +7 more sources
Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor [PDF]
Journal of Fungi, 2021 Ibrexafungerp (formerly SCY-078 or MK-3118) is a first-in-class triterpenoid antifungal or “fungerp” that inhibits biosynthesis of β-(1,3)-D-glucan in the fungal cell wall, a mechanism of action similar to that of echinocandins.
Sabelle Jallow, Nelesh P. Govender
doaj +4 more sources
Ibrexafungerp: A narrative overview
Current Research in Microbial SciencesIbrexafungerp (IBX) is a new antifungal drug that recently entered the antifungal landscape. It disrupts fungal cell wall synthesis by non-competitive inhibition of the β-(1,3)-D-glucan (BDG) synthase enzyme.
L'Emir Wassim El Ayoubi +3 more
doaj +4 more sources
Drug Design, Development and Therapy, 2023 Nancy A Phillips, Maria Rocktashel, Lena Merjanian Department Obstetrics, Gynecology & Reproductive Sciences, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USACorrespondence: Nancy A Phillips, Department Obstetrics, Gynecology ...
Phillips NA, Rocktashel M, Merjanian L
doaj +4 more sources
Journal of Fungi, 2022 Invasive fungal diseases (IFD) remain a major cause of morbidity and mortality in hematological patients, especially those undergoing hematopoietic stem cell transplantation (HSCT).
Justinas Daraskevicius +3 more
doaj +4 more sources
Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata [PDF]
Frontiers in Cellular and Infection Microbiology, 2021 Systemic infections caused by Candida species are an important cause of morbidity and mortality among immunocompromised and non-immunocompromised patients.
Ahmed Gamal +7 more
doaj +4 more sources
A Mini-Review of In Vitro Data for Candida Species, Including C. auris, Isolated during Clinical Trials of Three New Antifungals: Fosmanogepix, Ibrexafungerp, and Rezafungin [PDF]
Journal of FungiThis mini-review summarizes the clinical outcomes and antifungal susceptibility results, where available, for three new antifungals, including fosmanogepix, ibrexafungerp, and rezafungin, against Candida isolates cultured from patients in clinical trials.
Ana Espinel-Ingroff +1 more
doaj +3 more sources
In vitro activity of ibrexafungerp and comparators against Candida albicans genotypes from vaginal samples and blood cultures [PDF]
Clinical Microbiology and Infection, 2021 Objectives: Emergence of azole resistance may contribute to recurrences of vulvovaginal candidiasis. Thus, new drugs are needed to improve the therapeutic options.
Escribano, Pilar +7 more
core +6 more sources
Акушерство, гинекология и репродукцияIntroduction. Vulvovaginal candidiasis is an extremely common pathology of the female genital organs, leading to a long-term recurrent course and multiple complications.
L. I. Tagirova +11 more
doaj +3 more sources
Ibrexafungerp: A Novel Oral Triterpenoid Antifungal. [PDF]
Indian Dermatol Online J, 2023 Francis D, Rajiv SV, George M.
europepmc +4 more sources